Jazz Pharmaceuticals company profile
Company profile
Jazz Pharmaceuticals has 2,890 employees and is headquartered in Dublin, Ireland.
Sales are concentrated in the United States, which generated 89.8% of revenue, while Europe contributed 8.0% and other countries 2.2%. The company identifies, develops and commercializes pharmaceutical products, with Xywav treating narcolepsy and idiopathic hypersomnia, Epidiolex treating seizures linked to rare epilepsy syndromes, and Rylaze and Enrylaze treating acute lymphoblastic leukemia. Its oncology range also includes Zepzelca for small cell lung cancer, Ziihera for biliary tract cancers and Modeyso for diffuse midline glioma. Pipeline programs cover zanidatamab, dordaviprone and Vyxeos in further indications, and the company works with partners such as Zymeworks and Sumitomo Pharma.
In the fiscal year ended December 2025, revenue reached 4.3 billion US dollars, up 4.9% from the previous year, while the company posted a net loss of 356.1 million dollars. Jazz Pharmaceuticals has 2,890 employees, and its headquarters are in Dublin, Ireland. The company dates from 2003.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- Waterloo Exchange, D04 E5W7, Dublin
- Employees
- 2,890
- Chief executive
- Renee Gala
- Founded
- 2003
- Fiscal year
- January - December
- Listing
- JAZZ · NASDAQ
- Currency
- USD
- ISIN
- IE00B4Q5ZN47
- Website
- jazzpharma.com
Jazz Pharmaceuticals and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Jazz PharmaceuticalsJAZZ | United States | $15.5B | 2,890 | 27.4% | 71.5 |
| BridgeBio PharmaBBIO | United States | $15.25B | 1,081 | -37.3% | — |
| ExelixisEXEL | United States | $16.37B | 1,077 | 40.2% | 20.1 |
| Halozyme TherapeuticsHALO | United States | $14.67B | 423 | 56.8% | 38.3 |
| Ascendis PharmaASND | United States | $18.06B | 1,189 | 30.9% | 18.1 |
| Bio-TechneTECH | United States | $11.43B | 3,000 | 21.7% | 66.8 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
